M&A Deal Summary |
|
|---|---|
| Date | 2025-03-26 |
| Target | Aadi Sub |
| Sector | Life Science |
| Buyer(s) | Kaken Pharmaceutical |
| Sellers(s) | Whitehawk Therapeutics |
| Deal Type | Divestiture |
| Deal Value | 100M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1948 |
| Sector | Life Science |
| Employees | 1,143 |
| Revenue | 72.0B JPY (2024) |
Kaken Pharmaceutical is a specialty and generic drug manufacturing company. The Company's products are mainly for nervous, circulatory, respiratory, digestive, urinary, sensory, and metabolic systems. Kaken Pharmaceutical was founded in 1948 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2025) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Life Science |
| Revenue | 24M USD (2023) |
Whitehawk Therapeutics is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Whitehawk Therapeutics was founded in 2007 and is headquartered in Morristown, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2025) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
